Clinical trial
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
NCT02314481
Study timeline
Study start (actual)2017-05-12Date precision: day
Registry last updated2026-05-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancerunresolved
Interventions
MPDL3280ADRUG
VemurafenibDRUG · verified · RxNorm: vemurafenib
AlectinibDRUG · verified · RxNorm: alectinib
Sponsors & collaborators
University College, Londonlead sponsor
Hoffmann-La Rochecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02314481 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.